SCHEMBL5565448

SCHEMBL5565448

C=C(C(=O)c1ccc(S(=O)(=O)Nc2cc[nH]n2)cc1)c1cc(-c2cccs2)c(OC)cc1OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
RXFP1 Q9HBX9 3/20 0.35
KMT2A Q03164 3/20 0.35
TNFRSF1A P19438 2/20 0.35
MAPT P10636 1/20 0.35
GHSR Q92847 6/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
EDNRB P24530 1/20 0.35
EDNRA P25101 1/20 0.35
ALOX12 P18054 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TUBB4A P04350 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5560946 0.87 RXFP1 (0.49) RXFP1KMT2ASMN1; SMN2POLBHPGD
SCHEMBL5564202 0.86 HPGD (0.49) CA2CA9KMT2AMAPTPOLB
SCHEMBL5565466 0.86 SCN9A (0.41) CA2CA9
SCHEMBL5566988 0.85 KMT2A (0.51) RXFP1KMT2ASMN1; SMN2POLBHPGD
SCHEMBL5565512 0.85 SLC22A12 (0.42) KMT2A
SCHEMBL5565133 0.85 HTT (0.46) RXFP1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL5560084 0.85 HPGD (0.49) CA2CA9KMT2AMAPTPOLB
SCHEMBL5565370 0.85 MEN1 (0.51) RXFP1KMT2APOLBMAPK1ALOX12
SCHEMBL5560048 0.83 TNFRSF1A (0.42) TNFRSF1A
SCHEMBL6879563 0.81 TNFRSF1A (0.41) CA2CA9RXFP1KMT2ATNFRSF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US claimed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US claimed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US claimed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO claimed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 CA2 899/4885CA9 1619/4885RXFP1 4125/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 CA2 899/4885CA9 1619/4885RXFP1 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.